Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11055173 | 0.87 | TAS2R14 (0.60) | GAAMEN1KMT2AMAPTHTT | |
| SCHEMBL6063344 | 0.87 | CYP1A2 (0.57) | GAAMEN1KMT2AMAPTHTT | |
| SCHEMBL31245754 | 0.87 | CYP1A2 (0.57) | GAAMEN1KMT2AMAPTHTT | |
| SCHEMBL11775650 | 0.86 | GAA (0.49) | GAAMEN1KMT2AMAPTHTT | |
| SCHEMBL14934144 | 0.86 | EPHX2 (0.51) | GAAMEN1KMT2AMAPTHTT | |
| SCHEMBL8946084 | 0.84 | GAA (0.48) | GAAMEN1KMT2AMAPTHTT | |
| SCHEMBL14014937 | 0.84 | MAPT (0.56) | GAAMEN1KMT2AMAPTHTT | |
| SCHEMBL19358889 | 0.84 | KIF11 (0.56) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL18702740 | 0.83 | NR1H4 (0.56) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL24119880 | 0.83 | ALDH1A1 (0.54) | GAAMEN1KMT2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3359536-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| WO-2017062581-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2009009411-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| US-7449493-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1000067-B1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-10-23 | — | — | EP | disclosed |
| US-6369221-B1 | Thiazolobenzoheterocycles, preparation and medicines containing same | AVENTIS PHARMA S.A. (FR) | 2002-04-09 | — | — | US | disclosed |
| EP-1000067-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005147-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1999-02-04 | — | — | WO | disclosed |
| US-4433999-A | THIOCARBAMATES, CARBAMATE AND AN ANTIDOTE | STAUFFER CHEMICAL COMPANY (US) | 1984-02-28 | — | — | US | disclosed |
| US-4299616-A | THIOLCARBAMATES IN COMBINATION WITH SUBSTITUTED CARBAMATES | STAUFFER CHEMICAL COMPANY (US) | 1981-11-10 | — | — | US | disclosed |
| EP-0038945-A2 | Herbicide compositions of extended soil life | STAUFFER CHEMICAL COMPANY (US) | 1981-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | GAA 266/4885MEN1 4387/4885KMT2A 4758/4885 |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | GAA 266/4885MEN1 4387/4885KMT2A 4758/4885 |
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | GAA 266/4885MEN1 4387/4885KMT2A 4758/4885 |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | GAA 266/4885MEN1 4387/4885KMT2A 4758/4885 |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | GAA 266/4885MEN1 4387/4885KMT2A 4758/4885 |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | GAA 1465/4885MEN1 1311/4885KMT2A 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.